XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.19.1

Other assets impairments, restructuring and other items | 3 Months Ended
--- | ---
Mar. 31, 2019
Other assets impairments, restructuring and other items | NOTE 14 – Other assets impairments, restructuring and other items:
|  | Three months ended March 31, |
|  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
Impairments of long-lived tangible assets (1) |  | $ | 20 |  |  | $ | 226 |
Contingent consideration |  |  | (71 | ) |  |  | 8 |
Restructuring |  |  | 32 |  |  |  | 247 |
Other |  |  | 20 |  |  |  | 20 |
Total |  | $ | 1 |  |  | $ | 501 |
(1) | Including impairments related to exit and disposal activities
Impairments Impairments of property, plant and equipment for the first three months of 2019 were $20 million, consisting mainly of impairment of lease-related assets in North America. As a result of Teva’s plant rationalization acceleration in connection with the two year restructuring plan announced in December, 2017, to the extent the Company changes its plans on any given asset and/or the assumptions underlying such plans, there may be additional impairments in the future. Contingent consideration In the three months ended March 31, 2019, Teva recorded $71 million of contingent consideration income, compared to $8 million expense in the three months ended March 31, 2018. The income in the first quarter of 2019 mainly related to the decrease in the expected royalty payments in connection with lenalidomide (generic equivalent of Revlimid ® ) which was part of the Actavis acquisition. Restructuring In the three months ended March 31, 2019, Teva recorded $32 million of restructuring expenses, compared to $247 million in the three months ended March 31, 2018. Since the announcement of its restructuring plan, Teva reduced its global headcount by approximately 10,400 full-time-equivalent employees. The following tables provide the components of costs associated with Teva’s restructuring plan, including other costs associated with Teva’s restructuring plan and recorded under different items:
|  | Three months ended March 31, |
|  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
Restructuring |  |  |  |  |  |  |  |
Employee termination |  | $ | 20 |  |  | $ | 228 |
Other |  |  | 12 |  |  |  | 19 |
Total |  | $ | 32 |  |  | $ | 247 |
The following table provides the components of and changes in the Company’s restructuring accruals:
|  | Employee termination costs |  |  | Other |  |  | Total |
|  | (U.S. $ in millions ) |
Balance as of January 1, 2019 |  | $ | (204 | ) |  | $ | (29 | ) |  | $ | (233 | )
Provision |  |  | (20 | ) |  |  | (12 | ) |  |  | (32 | )
Utilization and other* |  |  | 32 |  |  |  | 34 |  |  |  | 66 |
Balance as of March 31, 2019 |  | $ | (192 | ) |  | $ | (7 | ) |  | $ | (199 | )
* | Includes adjustments for foreign currency translation.
Significant regulatory events In July 2018, the FDA completed an inspection of Teva’s manufacturing plant in Davie, Florida in the United States, and issued a Form FDA-483 to the site. In October 2018, the FDA notified Teva that the inspection of the site is classified as “official action indicated” (OAI). On February 5, 2019, Teva received a warning letter from the FDA that contains four enumerated concerns related to production, quality control, and investigations at this site. Teva is working diligently to remediate the FDA’s concerns in a manner consistent with current good manufacturing practice (CGMP) requirements, and to address those concerns as quickly and as thoroughly as possible. If Teva is unable to remediate the warning letter findings to the FDA’s satisfaction, it may face additional consequences, including delays in FDA approval for future products from the site, financial implications due to loss of revenues, impairments, inventory write offs, customer penalties, idle capacity charges, costs of additional remediation and possible FDA enforcement action. Teva expects to generate approximately $240 million in revenues from this site for the remainder of 2019, assuming remediation or enforcement does not cause any unscheduled slowdown or stoppage at the facility. In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown impurity called NDMA found in valsartan API supplied to Teva by Zhejiang Huahai Pharmaceutical. Since July 2018, Teva has been actively engaged with regulatory agencies around the world in reviewing its valsartan and other sartan products for NDMA and other related impurities and, where necessary, has initiated additional voluntary recalls. The impact of this recall on Teva’s 2018 financial statements was $51 million, primarily related to inventory reserves. Teva expects to continue to experience loss of revenues and profits in connection with this matter. In addition, multiple lawsuits have been filed in connection with this matter, for which litigation costs are currently being incurred. Teva may also incur additional customer penalties, impairments and litigation costs going forward.

X
- Definition Other Expenses [Text Block] + References No definition available. + Details
Name: | teva_OtherExpensesTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration